Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Summary on May 17, 2018

May 17, 2018 - By Cynthia Ashman

Seattle Genetics, Inc. (NASDAQ:SGEN) Corporate Logo
Big Money Sentiment increased to 1.23 in Q4 2017. It has change of 0.45, from 2017Q3’s 0.78. The ratio improved due to Seattle Genetics, Inc. positioning: 24 sold and 67 reduced. 44 funds acquired holdings and 68 increased holdings. Investors holded 140.23 million in 2017Q3 but now own 141.83 million shares or 1.14% more.
Moreover, Baker Bros Advsrs L P has 21.2% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 45.73M shs. Vantage Advisors Ltd Liability Corporation has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Credit Suisse Ag reported 134,621 shs stake. Deutsche Fincl Bank Ag accumulated 335,989 shs. Bluecrest Limited holds 0.01% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN) for 6,280 shs. Blair William And Il owns 657,498 shs. 14.96 million are held by Baillie Gifford And. Dupont Mgmt Corp holds 0.01% or 7,861 shs in its capital. Wellington Mngmt Group Incorporated Limited Liability Partnership stated it has 115,103 shs or 0% of all its holdings. 6,241 are owned by Nbt Natl Bank N A. Raymond James And Associates owns 5,800 shs. Envestnet Asset invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Wasatch Advsr stated it has 0.69% in Seattle Genetics, Inc. (NASDAQ:SGEN). Aperio Grp Llc stated it has 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Renaissance Tech Ltd Liability Corp holds 0% or 43,113 shs in its capital.

Seattle Genetics, Inc. had 10 sales and 3 insider buys since December 11, 2017. This’s net activity of $268.25 million. On Thursday, February 1 BAKER BROS. ADVISORS LP bought $200.00 million worth of Seattle Genetics, Inc. (NASDAQ:SGEN) or 3.85M shs. Shares for $215,238 were sold by Cline Darren S on Thursday, May 3. On Thursday, March 15 HIMES VAUGHN B had sold 5,000 shs worth $290,604. $552,452 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) was sold by DRACHMAN JONATHAN G.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Total analysts of 8 have positions in Seattle Genetics (NASDAQ:SGEN) as follows: 6 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 75%. Since January 31, 2018 according to StockzIntelligence Inc Seattle Genetics has 11 analyst reports. In Wednesday, January 31 report RBC Capital Markets maintained the stock with “Buy” rating. On Wednesday, February 14 the rating was upgraded by JP Morgan to “Overweight”. On Thursday, February 1 the company was maintained by H.C. Wainwright. On Wednesday, February 7 the rating was maintained by Bank of America with “Neutral”. On Wednesday, February 7 the firm earned “Buy” rating by H.C. Wainwright. In Wednesday, February 14 report J.P. Morgan upgraded it to “Buy” rating and $66.0 target. In Friday, April 27 report H.C. Wainwright maintained the stock with “Buy” rating. On Wednesday, March 21 Morgan Stanley maintained the shares of SGEN in report with “Overweight” rating. On Wednesday, February 7 the rating was maintained by SunTrust with “Hold”. On Tuesday, March 20 the rating was maintained by RBC Capital Markets with “Buy”. Listed here are Seattle Genetics, Inc. (NASDAQ:SGEN) PTs and latest ratings.

27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $75.0 Maintain

Ticker’s shares touched $57.33 during the last trading session after 2.00% change.Currently Seattle Genetics, Inc. is downtrending after 20.48% change in last May 17, 2017. SGEN has also 910,426 shares volume. SGEN underperformed by 32.03% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide.The firm is valued at $9.07 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.Last it reported negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

For more Seattle Genetics, Inc. (NASDAQ:SGEN) news brought out recently go to: Seekingalpha.com, Businesswire.com, Nasdaq.com, Businesswire.com or Streetinsider.com. The titles are as follows: “Seattle Genetics (SGEN) Q1 2018 Results – Earnings Call Transcript” brought out on April 27, 2018, “Seattle Genetics Appoints Roger D. Dansey, MD, Chief Medical Officer” on May 17, 2018, “Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags …” with a publish date: May 09, 2018, “Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting” and the last “Seattle Genetics (SGEN) Announces Data Presentations at ASCO” with publication date: May 17, 2018.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.